CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome (CACOLAC)
Primary Purpose
ARDS Secondary to COVID-19 Pneumonia
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
L-citrulline
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for ARDS Secondary to COVID-19 Pneumonia
Eligibility Criteria
Inclusion Criteria:
- Age greater than or equal to 18 years;
- Patients admitted for less than 48 hours in intensive care for ARDS under mechanical ventilation according to the Berlin criteria published in 2012 (JAMA);
- Origin of ARDS: COVID-19 pneumopathy confirmed by PCR (nasopharyngeal or tracheal sample);
- Life expectancy> 2 days;
- Affiliated to a social security scheme;
- Consent signed by the patient, the relative or the legal representative (except emergency procedure).
Exclusion Criteria:
- Pregnancy or breastfeeding in progress;
- State of immunosuppression defined by at least one of these criteria: continuous administration of steroids at any dose for more than a month before hospitalization, steroids in high doses (> 15 mg / kg / day of methylprednisolone or equivalent), radiotherapy or chemotherapy in the previous year, proven humoral or cellular deficiency;
- Contraindication to enteral nutrition (2016 SRLF recommendations: "Enteral nutrition probably should not be used upstream of a high-flow digestive fistula in the event of intestinal obstruction, small ischemia or digestive hemorrhage active (Strong chord) ").
- Ongoing immunosuppressive therapy such as chemotherapy, cyclophosphamide, high dose corticosteroid therapy (> 15 mg / kg / day);
- Participation in intervention research on a drug, or intervention research that may impact the immune system.
Sites / Locations
- Rennes University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
L-citrulline
Placebo
Arm Description
Administration of citrulline enterally for 7 days
Administration of placeboenterally for 7 days
Outcomes
Primary Outcome Measures
SOFA
SOFA score for organ failures on D8 or last known SOFA score if the patient has died or been resuscitated
Secondary Outcome Measures
Number and phenotype of lymphocytes
Number and phenotype of lymphocytes on days 1, 8 and 14
HLA-DR
Monocytic expression HLA-DR (Flow cytometry) on days 1, 8 and 14
Number of Myeloid-derived suppressor cells
Number of Myeloid-derived suppressor cells (Flow cytometry) on days 1, 8 and 14
Plasma cytokines / chemokines
Plasma cytokines / chemokines (IL-6, IL-8, IL-10, IL-7, CXCL10, G-CSF, TNF-alpha, IFN-β) at days 1, 8 and 14
Repertoire T
Diversity of the repertoire T at days 1, 3, 8, 10 and 14
Lymphocyte T exhaustion
T lymphocyte exhaustion: measurement of lymphocyte apoptosis and lymphocyte proliferation on days 1, 8 and 14
Mitochondrial activity
Measurement of mitochondrial activity (measurement of the number of mitochondria and their membrane potential, measurement of the expression of Beclin1) on days 1, 8 and 14
Plasma amino acids
Plasma amino acids (arginine and its metabolites (ornithine, glutamate, glutamine, citrulline, proline) and tryptophan / kynurenine) on days 1, 8 and 14
SOFA
SOFA score of organ failures on days 3, 7, 10 and 14
Duration of hospitalization in intensive care
Duration of hospitalization in intensive care (days), up to day 28 maximum
Duration of hospital stay in hospital
Duration of hospital stay in hospital (days), up to day 28 maximum
Duration of mechanical ventilation
Duration of mechanical ventilation (days), up to day 28 maximum
Mortality in intensive care on day 28
Mortality in intensive care on day 28
Hospital mortality on day 28
Hospital mortality on day 28
Measurement of the presence of SARS-CoV2
Measurement of the presence of SARS-CoV2 in the tracheal aspiration by PCR on days 1, 8 and 14
Nosocomial infections
Incidence of nosocomial infections during the intensive care unit (maximum D28). The diagnosis of nosocomial infections will be made according to the definitions of nosocomial infections of the CDC. An independent committee of experts will validate or not the infections
Number of days of exposure to each antibiotic per 1000 days of hospitalization
Number of days of exposure to each antibiotic per 1000 days of hospitalization (maximum day 28).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04404426
Brief Title
CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome
Acronym
CACOLAC
Official Title
CACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
November 4, 2020 (Actual)
Primary Completion Date
March 25, 2021 (Actual)
Study Completion Date
May 28, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rennes University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Respiratory involvement of SARS-CoV2 leads to acute respiratory distress syndrome (ARDS) and significant immunosuppression (lymphopenia) exposing patients to long ventilation duration and late mortality linked to the acquisition of nosocomial infections.
Lymphopenia characteristic of severe forms of ARDS secondary to SARS-CoV2 infection may be linked to expansion of MDSCs and arginine depletion of lymphocytes.
Severe forms of COVID-19 pneumonitis are marked by persistent ARDS with acquisition of nosocomial infections as well as by prolonged lymphocytic dysfunction associated with the emergence of MDSC.
It has been found in intensive care patients hypoargininaemia, associated with the persistence of organ dysfunction (evaluated by the SOFA score), the occurrence of nosocomial infections and mortality. Also, it has been demonstrated that in these patients, the enteral administration of ARG was not deleterious and increased the synthesis of ornithine, suggesting a preferential use of ARG by the arginase route, without significant increase in argininaemia nor effect on immune functions. L-citrulline (CIT), an endogenous precursor of ARG, is an interesting alternative to increase the availability of ARG. Recent data demonstrate that the administration of CIT in intensive care is not deleterious and that it very significantly reduces mortality in an animal model of sepsis, corrects hypoargininemia, with convincing data on immunological parameters such as lymphopenia, which is associated with mortality, organ dysfunction and the occurrence of nosocomial infections. The availability of ARG directly impacts the mitochondrial metabolism of T lymphocytes and their function. The hypothesis is therefore that CIT supplementation is more effective than the administration of ARG to correct hypoargininaemia, decrease lymphocyte dysfunction, correct immunosuppression and organ dysfunction in septic patients admitted to intensive care.
The main objective is to show that, in patients hospitalized in intensive care for ARDS secondary to COVID-19 pneumonia, the group of patients receiving L-citrulline for 7 days, compared to the group receiving placebo, has a score of organ failure decreased on D7 (evaluated by the SOFA score) or by the last known SOFA score if the patient has died or been resuscitated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ARDS Secondary to COVID-19 Pneumonia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, multicenter, placebo-controlled, randomized, double-blind, two-parallel study, specific enteral administration by citrulline in a subgroup of resuscitation patients admitted for ARDS secondary to COVID-19 pneumonia, at infectious risk nosocomial important because having biological stigmas of immunosuppression on admission and under invasive mechanical ventilation for a prolonged period.
Masking
ParticipantCare ProviderInvestigator
Masking Description
Double-blind
Allocation
Randomized
Enrollment
33 (Actual)
8. Arms, Groups, and Interventions
Arm Title
L-citrulline
Arm Type
Experimental
Arm Description
Administration of citrulline enterally for 7 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Administration of placeboenterally for 7 days
Intervention Type
Dietary Supplement
Intervention Name(s)
L-citrulline
Intervention Description
Administration of citrulline enterally for 7 days.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Administration of placebo (water) enterally for 7 days
Primary Outcome Measure Information:
Title
SOFA
Description
SOFA score for organ failures on D8 or last known SOFA score if the patient has died or been resuscitated
Time Frame
Day 8
Secondary Outcome Measure Information:
Title
Number and phenotype of lymphocytes
Description
Number and phenotype of lymphocytes on days 1, 8 and 14
Time Frame
Days 1, 8 and 14
Title
HLA-DR
Description
Monocytic expression HLA-DR (Flow cytometry) on days 1, 8 and 14
Time Frame
Days 1, 8 and 14
Title
Number of Myeloid-derived suppressor cells
Description
Number of Myeloid-derived suppressor cells (Flow cytometry) on days 1, 8 and 14
Time Frame
Days 1, 8 and 14
Title
Plasma cytokines / chemokines
Description
Plasma cytokines / chemokines (IL-6, IL-8, IL-10, IL-7, CXCL10, G-CSF, TNF-alpha, IFN-β) at days 1, 8 and 14
Time Frame
Days 1, 8 and 14
Title
Repertoire T
Description
Diversity of the repertoire T at days 1, 3, 8, 10 and 14
Time Frame
Days 1, 3, 8, 10 and 14
Title
Lymphocyte T exhaustion
Description
T lymphocyte exhaustion: measurement of lymphocyte apoptosis and lymphocyte proliferation on days 1, 8 and 14
Time Frame
Days 1, 8 and 14
Title
Mitochondrial activity
Description
Measurement of mitochondrial activity (measurement of the number of mitochondria and their membrane potential, measurement of the expression of Beclin1) on days 1, 8 and 14
Time Frame
Days 1, 8 and 14
Title
Plasma amino acids
Description
Plasma amino acids (arginine and its metabolites (ornithine, glutamate, glutamine, citrulline, proline) and tryptophan / kynurenine) on days 1, 8 and 14
Time Frame
Days 1, 8 and 14
Title
SOFA
Description
SOFA score of organ failures on days 3, 7, 10 and 14
Time Frame
Days 3, 7, 10 and 14
Title
Duration of hospitalization in intensive care
Description
Duration of hospitalization in intensive care (days), up to day 28 maximum
Time Frame
Day 28
Title
Duration of hospital stay in hospital
Description
Duration of hospital stay in hospital (days), up to day 28 maximum
Time Frame
Day 28
Title
Duration of mechanical ventilation
Description
Duration of mechanical ventilation (days), up to day 28 maximum
Time Frame
Day 28
Title
Mortality in intensive care on day 28
Description
Mortality in intensive care on day 28
Time Frame
Day 28
Title
Hospital mortality on day 28
Description
Hospital mortality on day 28
Time Frame
Day 28
Title
Measurement of the presence of SARS-CoV2
Description
Measurement of the presence of SARS-CoV2 in the tracheal aspiration by PCR on days 1, 8 and 14
Time Frame
Days 1, 8 and 14
Title
Nosocomial infections
Description
Incidence of nosocomial infections during the intensive care unit (maximum D28). The diagnosis of nosocomial infections will be made according to the definitions of nosocomial infections of the CDC. An independent committee of experts will validate or not the infections
Time Frame
D28
Title
Number of days of exposure to each antibiotic per 1000 days of hospitalization
Description
Number of days of exposure to each antibiotic per 1000 days of hospitalization (maximum day 28).
Time Frame
Day 28
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age greater than or equal to 18 years;
Patients admitted for less than 48 hours in intensive care for ARDS under mechanical ventilation according to the Berlin criteria published in 2012 (JAMA);
Origin of ARDS: COVID-19 pneumopathy confirmed by PCR (nasopharyngeal or tracheal sample);
Life expectancy> 2 days;
Affiliated to a social security scheme;
Consent signed by the patient, the relative or the legal representative (except emergency procedure).
Exclusion Criteria:
Pregnancy or breastfeeding in progress;
State of immunosuppression defined by at least one of these criteria: continuous administration of steroids at any dose for more than a month before hospitalization, steroids in high doses (> 15 mg / kg / day of methylprednisolone or equivalent), radiotherapy or chemotherapy in the previous year, proven humoral or cellular deficiency;
Contraindication to enteral nutrition (2016 SRLF recommendations: "Enteral nutrition probably should not be used upstream of a high-flow digestive fistula in the event of intestinal obstruction, small ischemia or digestive hemorrhage active (Strong chord) ").
Ongoing immunosuppressive therapy such as chemotherapy, cyclophosphamide, high dose corticosteroid therapy (> 15 mg / kg / day);
Participation in intervention research on a drug, or intervention research that may impact the immune system.
Facility Information:
Facility Name
Rennes University Hospital
City
Rennes
State/Province
Britanny
ZIP/Postal Code
35000
Country
France
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome
We'll reach out to this number within 24 hrs